Life and health is the eternal topic of mankind, the symbol of human civilization and progress and the basis of comprehensive and sustainable social development. Combing the major infectious diseases in the world over the past 30 years, from 1990s H5N1 influenza, 2003 SARS, 2011 polio, Ebola, MERS and H7N9 avian influenza in 2013, the Chai card in 2016 and dengue fever in 2017, these major infectious diseases have been epidemic in some areas and even globally. It is gratifying to note that SARS has disappeared and polio has been controlled. Through the continuous progress of science and technology, H5N1 influenza, Ebora and H7N9 avian influenza have all developed effective vaccines. However, we also regret to see that there is no vaccine for infectious diseases such as mers, Zika and dengue fever, which can not be effectively prevented in some underdeveloped areas. The novel coronavirus pneumonia has caused mankind to face the most serious public health emergencies since the end of the Second World War. The virus has no borders, and the epidemic has spread to more than 210 countries and regions. It poses a severe challenge to human survival and international order. No country can be single handed. It must work hand in hand to promote global cooperation in anti epidemic. Jointly build a community of human health. Novel coronavirus pneumonia is the most powerful weapon for human beings to overcome diseases. In the face of the new crown pneumonia epidemic, countries are focusing their efforts on technology epidemic, especially vaccine research and development. By October 2021, 322 new coronal vaccines had been developed worldwide and 128 had entered clinical research, creating an unprecedented scale and speed of vaccine research and development in human history. After the outbreak, China actively invested in science and technology, took the lead in releasing the virus gene sequence, shared the experience of prevention, control and treatment, took the lead in providing anti epidemic materials to various countries in large quantities, took the lead in sending medical expert groups abroad, and promised to take China's new crown vaccine as a global public product. As a leading enterprise in China's pharmaceutical industry and a national innovative enterprise, Sinopharm group gives full play to the role of innovation subject, fully carries out scientific research and research, and develops four new crown vaccines in three technical routes. On December 9, 2020, Sinopharm Xinguan inactivated vaccine was approved in the UAE, becoming the first officially registered new crown vaccine in the world. On May 7, 2021, the national medicine vaccine passed the WHO emergency use certification. Gao Li, who representative in China, said that China has opened a new chapter in the global supply of public health products with its R & D capacity and production capacity and its commitment to make great contributions to global health. Over the past year, we have strengthened investment in science and technology and promoted the iterative upgrading of vaccines. Effective second-generation inactivated vaccines have been launched against beta and delta mutant strains, and second-generation recombinant protein vaccines and mRNA vaccines with broad-spectrum neutralization efficacy against all virus variants have been developed. According to the Research Report on the effectiveness of the vaccine from Sri Lanka kasri jayawad napura University, the Sinopharm new crown inactivated vaccine is very effective for the mutant delta strain. Over the past year, we have shared research results and enhanced global scientific and technological cooperation. Chinese pharmaceutical scientists have published papers in more than 10 internationally renowned academic journals such as the lancet, cell and JAMA, discussed and interacted with scientists from various countries, and shared the research results and core data of Chinese vaccine R & D and clinical trials to the world. Over the past year, we have promoted transnational experiments and real-world research. In more than 20 countries such as Europe, America and Africa, experiments were carried out in collaboration with local institutions. In July this year, with the support of the epidemic prevention Innovation Alliance (CEPI), we carried out in-depth cooperation with the International Vaccine Research Institute (IVI), the National Research Institute of Mozambique, the international diarrhea research center of Bangladesh, the University of Heidelberg in Germany and Harvard University in the United States to study the protective effect of the vaccine on mutant strains in different populations in designated areas. Over the past year, we have practiced vaccine cooperation and let the world share China's achievements in scientific and technological anti epidemic. Accelerate the expansion of production capacity, build three P3 high-level biosafety laboratories and six P3 high-level biosafety production workshops, with an annual production capacity of more than 7 billion doses, which is capable of meeting the needs at home and abroad. Strengthen technology transfer, successively carry out production cooperation with the United Arab Emirates, Serbia, Morocco and other countries, and continue to explore overseas plant construction and more cooperation with many countries in Southeast Asia and South America. Fair and reasonable novel coronavirus pneumonia global distribution mechanism is being promoted under the coordination of WHO, and the vaccine purchase agreement has been signed with the global alliance for vaccines and immunization (GAVI). The vaccine will provide 170 million doses of national vaccine to the new crown vaccine implementation plan (COVAX). Strengthen international cooperation on vaccines. At present, Sinopharm vaccine has been approved for registration, listing or emergency use in 112 countries, regions and international organizations. The vaccinated population covers 196 countries, becoming one of the most widely used and supplied new vaccines in the world. The key to victory over COVID-19 is technology. China's vaccine, as a result of hard core technology, has made important contributions to the establishment of global immune barriers. It has received wide acclaim from the international community. Zimbabwe President Mnangagwa said China's vaccine is like "the light at the end of the tunnel", bringing hope to the government and people of Zimbabwe. Richard hachett, CEO of the epidemic prevention innovation alliance, said that "by rapidly developing a variety of vaccines and sharing vaccines around the world, China has made great contributions to promoting the fairness and accessibility of the new crown vaccine". In the face of repeated COVID-19, China pharmaceutical enterprises and other Chinese enterprises will accelerate technological research, enhance strategic and technological strength, transform institutional advantages into technological advantages, transform technological capabilities into research results, master more core technologies, and produce more hard core products to protect people's lives and health, contributing to the construction of human health and health community. (outlook new era)